The European Fee at the moment (8 January) proposed to the EU Member States to buy an extra 200 million doses of the COVID-19 vaccine produced by BioNTech and Pfizer, with the choice to amass one other 100 million doses. This may allow the EU to buy as much as 600 million doses of this vaccine, which is already getting used throughout the EU.
The extra doses will likely be delivered beginning within the second quarter of 2021.
The EU has acquired a broad portfolio of vaccines with totally different applied sciences. It has secured as much as 2.3 billion doses from essentially the most promising vaccine candidates for Europe and its neighbourhood.
Along with the BioNTech-Pfizer vaccine, a second vaccine, produced by Moderna, was authorised on 6 January 2021. Different vaccines are anticipated to be accredited quickly.
This vaccine portfolio would allow the EU not solely to cowl the wants of its complete inhabitants, but additionally to produce vaccines to neighbouring nations.